JP2019510974A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510974A5 JP2019510974A5 JP2018549812A JP2018549812A JP2019510974A5 JP 2019510974 A5 JP2019510974 A5 JP 2019510974A5 JP 2018549812 A JP2018549812 A JP 2018549812A JP 2018549812 A JP2018549812 A JP 2018549812A JP 2019510974 A5 JP2019510974 A5 JP 2019510974A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleosome
- subject
- tissue
- transcription factor
- cofactor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000011510 cancer Diseases 0.000 claims description 41
- 206010028980 Neoplasm Diseases 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 36
- 108010047956 Nucleosomes Proteins 0.000 claims description 35
- 210000001623 nucleosome Anatomy 0.000 claims description 35
- 210000001519 tissue Anatomy 0.000 claims description 33
- 108091023040 Transcription factor Proteins 0.000 claims description 30
- 102000040945 Transcription factor Human genes 0.000 claims description 30
- 239000000126 substance Substances 0.000 claims description 24
- 239000013060 biological fluid Substances 0.000 claims description 18
- 238000011161 development Methods 0.000 claims description 14
- 238000013518 transcription Methods 0.000 claims description 10
- 230000035897 transcription Effects 0.000 claims description 9
- 239000000090 biomarker Substances 0.000 claims description 7
- 108010033040 Histones Proteins 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 108020004414 DNA Proteins 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 108091023037 Aptamer Proteins 0.000 claims description 2
- 101100189945 Arabidopsis thaliana PER63 gene Proteins 0.000 claims description 2
- 108010083123 CDX2 Transcription Factor Proteins 0.000 claims description 2
- 102000006277 CDX2 Transcription Factor Human genes 0.000 claims description 2
- 102100027893 Homeobox protein Nkx-2.1 Human genes 0.000 claims description 2
- 101710114425 Homeobox protein Nkx-2.1 Proteins 0.000 claims description 2
- 102100028092 Homeobox protein Nkx-3.1 Human genes 0.000 claims description 2
- 101000578249 Homo sapiens Homeobox protein Nkx-3.1 Proteins 0.000 claims description 2
- 101000601664 Homo sapiens Paired box protein Pax-8 Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 101100013967 Mus musculus Gata3 gene Proteins 0.000 claims description 2
- 102100037502 Paired box protein Pax-8 Human genes 0.000 claims description 2
- 108010029485 Protein Isoforms Proteins 0.000 claims description 2
- 102000001708 Protein Isoforms Human genes 0.000 claims description 2
- 101710088547 Thyroid transcription factor 1 Proteins 0.000 claims description 2
- 101150071739 Tp63 gene Proteins 0.000 claims description 2
- 101710159262 Transcription termination factor 1 Proteins 0.000 claims description 2
- 102100027881 Tumor protein 63 Human genes 0.000 claims description 2
- 102000040856 WT1 Human genes 0.000 claims description 2
- 108700020467 WT1 Proteins 0.000 claims description 2
- 101150084041 WT1 gene Proteins 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 238000005259 measurement Methods 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 206010073059 Malignant neoplasm of unknown primary site Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 108010077544 Chromatin Proteins 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1604806.8 | 2016-03-22 | ||
| GBGB1604806.8A GB201604806D0 (en) | 2016-03-22 | 2016-03-22 | Method of identifying a cancer of unknown origin |
| PCT/EP2017/056851 WO2017162755A1 (en) | 2016-03-22 | 2017-03-22 | Use of nucleosome-transcription factor complexes for cancer detection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019510974A JP2019510974A (ja) | 2019-04-18 |
| JP2019510974A5 true JP2019510974A5 (enExample) | 2020-08-27 |
| JP6777757B2 JP6777757B2 (ja) | 2020-10-28 |
Family
ID=55968658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018549812A Active JP6777757B2 (ja) | 2016-03-22 | 2017-03-22 | 癌検出のためのヌクレオソーム−転写因子複合体の使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20200363418A1 (enExample) |
| EP (3) | EP4270007A3 (enExample) |
| JP (1) | JP6777757B2 (enExample) |
| KR (2) | KR102369544B1 (enExample) |
| CN (1) | CN109313192B (enExample) |
| AU (1) | AU2017238442A1 (enExample) |
| CA (1) | CA3018428C (enExample) |
| ES (2) | ES2861440T5 (enExample) |
| GB (1) | GB201604806D0 (enExample) |
| MY (1) | MY187655A (enExample) |
| SG (1) | SG11201807991QA (enExample) |
| WO (1) | WO2017162755A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202238131A (zh) | 2020-11-25 | 2022-10-01 | 比利時商比利時意志有限公司 | 測量無細胞核蛋白染色質片段之方法 |
| TW202242145A (zh) | 2020-12-29 | 2022-11-01 | 比利時商比利時意志有限公司 | 核小體耗盡循環無細胞染色質片段之轉錄因子結合位點分析 |
| TW202242130A (zh) | 2020-12-29 | 2022-11-01 | 比利時商比利時意志有限公司 | 循環轉錄因子分析 |
| US20240318259A1 (en) * | 2021-09-24 | 2024-09-26 | Oncocross Co., Ltd. | Method for determining primary tumor site |
| TW202530419A (zh) | 2023-10-04 | 2025-08-01 | 比利時商比利時意志有限公司 | Pcr方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1274861B1 (en) * | 2000-03-27 | 2009-12-23 | Thomas Jefferson University | Compositions and methods for identifying and targeting cancer cells |
| WO2003025583A2 (en) * | 2001-09-14 | 2003-03-27 | F. Hoffmann-La Roche Ag | Differential diagnosis of disorders of iron metabolism |
| US7248921B2 (en) * | 2003-06-02 | 2007-07-24 | Cameron Health, Inc. | Method and devices for performing cardiac waveform appraisal |
| US20040018525A1 (en) * | 2002-05-21 | 2004-01-29 | Bayer Aktiengesellschaft | Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasma |
| US20040236188A1 (en) * | 2003-05-19 | 2004-11-25 | Ge Medical Systems Information | Method and apparatus for monitoring using a mathematical model |
| US8029989B2 (en) * | 2005-08-26 | 2011-10-04 | The Trustees Of The University Of Pennsylvania | Method using snail transcriptional repressor |
| US20090298097A1 (en) * | 2007-07-17 | 2009-12-03 | Harris Pamela J | Methods for the diagnosis of lung cancer |
| WO2010001933A1 (ja) * | 2008-07-01 | 2010-01-07 | 学校法人日本大学 | 標的遺伝子特異的ヒストン修飾制御剤 |
| MY148542A (en) * | 2009-06-15 | 2013-04-30 | Cancer Res Initiatives Foundation | A method for the assessment of cancer in a biological sample obtained from a subject |
| EP2270510A1 (en) * | 2009-07-02 | 2011-01-05 | EMBL (European Molecular Biology Laboratory) | Diagnostic method for predicting the risk of cancer recurrence based on Histone macroH2A isoforms |
| GB201115095D0 (en) * | 2011-09-01 | 2011-10-19 | Singapore Volition Pte Ltd | Method for detecting nucleosomes containing nucleotides |
| GB201115098D0 (en) * | 2011-09-01 | 2011-10-19 | Belgian Volition Sa | Method for detecting nucleosomes containing histone variants |
| JP6263474B2 (ja) * | 2011-12-07 | 2018-01-17 | シンガポール ボリション ピーティーイー リミテッド | ヌクレオソームアダクト検出法 |
| GB201303576D0 (en) * | 2013-02-28 | 2013-04-10 | Singapore Volition Pte Ltd | Method for predicting therapy efficacy using nucleosome structure biomarkers |
-
2016
- 2016-03-22 GB GBGB1604806.8A patent/GB201604806D0/en not_active Ceased
-
2017
- 2017-03-22 MY MYPI2018703273A patent/MY187655A/en unknown
- 2017-03-22 KR KR1020217012412A patent/KR102369544B1/ko not_active Expired - Fee Related
- 2017-03-22 KR KR1020187029952A patent/KR102246699B1/ko not_active Expired - Fee Related
- 2017-03-22 AU AU2017238442A patent/AU2017238442A1/en not_active Abandoned
- 2017-03-22 WO PCT/EP2017/056851 patent/WO2017162755A1/en not_active Ceased
- 2017-03-22 US US16/087,060 patent/US20200363418A1/en not_active Abandoned
- 2017-03-22 EP EP23177260.9A patent/EP4270007A3/en not_active Withdrawn
- 2017-03-22 JP JP2018549812A patent/JP6777757B2/ja active Active
- 2017-03-22 SG SG11201807991QA patent/SG11201807991QA/en unknown
- 2017-03-22 EP EP17712782.6A patent/EP3433616B2/en active Active
- 2017-03-22 ES ES17712782T patent/ES2861440T5/es active Active
- 2017-03-22 CN CN201780031827.0A patent/CN109313192B/zh not_active Expired - Fee Related
- 2017-03-22 CA CA3018428A patent/CA3018428C/en active Active
- 2017-03-22 ES ES20210821T patent/ES2951136T3/es active Active
- 2017-03-22 EP EP20210821.3A patent/EP3839513B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017215338A5 (enExample) | ||
| CY1122871T1 (el) | Μεθοδος ποσοτικου προσδιορισμου για την εκφραση της pd-l1 | |
| Yang et al. | Predictors of severe and critical acute pancreatitis: a systematic review | |
| JP2014529405A5 (enExample) | ||
| Smadja et al. | Placental growth factor level in plasma predicts COVID‐19 severity and in‐hospital mortality | |
| RU2014112348A (ru) | Способ детекции нуклеосом, содержащих гистоновые варианты | |
| Metwalli et al. | Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer | |
| Zhao et al. | The significance of RDW in patients with hepatocellular carcinoma after radical resection | |
| Ondruschka et al. | Post-mortem in situ stability of serum markers of cerebral damage and acute phase response | |
| RU2014112350A (ru) | Способ детекции нуклеосом, содержащих нуклеотиды | |
| JP2016500110A5 (enExample) | ||
| JP2011526693A5 (enExample) | ||
| JP2018529931A5 (enExample) | ||
| Ye et al. | Building and verifying a severity prediction model of acute pancreatitis (AP) based on BISAP, MEWS and routine test indexes | |
| Gosselin et al. | Comparison of anti-Xa and dilute Russell viper venom time assays in quantifying drug levels in patients on therapeutic doses of rivaroxaban | |
| JP2014531573A5 (enExample) | ||
| JP2017508970A5 (enExample) | ||
| Fischer et al. | Serum amyloid A: a biomarker for renal cancer | |
| JP2017504011A5 (enExample) | ||
| Ferencik et al. | Highly sensitive troponin and coronary computed tomography angiography in the evaluation of suspected acute coronary syndrome in the emergency department | |
| Unruh et al. | Levels of alternatively spliced tissue factor in the plasma of patients with pancreatic cancer may help predict aggressive tumor phenotype | |
| Leong et al. | Sampling circulating tumor cells for clinical benefits: how frequent? | |
| Keskin et al. | Prognostic value of preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios, and multiphasic renal tomography findings in histological subtypes of renal cell carcinoma | |
| Zymliński et al. | Elevated troponin I level assessed by a new high-sensitive assay and the risk of poor outcomes in patients with acute heart failure | |
| JP2024501063A5 (enExample) |